Population Pharmacokinetics and Exposure–Response Analysis for the Phase 3 COSMIC-311 Trial of Cabozantinib for Radioiodine-Refractory Differentiated Thyroid Cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Population Pharmacokinetics and Exposure–Response Analysis for the Phase 3 COSMIC-311 Trial of Cabozantinib for Radioiodine-Refractory Differentiated Thyroid Cancer ; volume:62 ; number:4 ; day:4 ; month:3 ; year:2023 ; pages:587-598 ; date:4.2023
Clinical pharmacokinetics ; 62, Heft 4 (4.3.2023), 587-598, 4.2023
- Creator
-
Ly, Neang S.
Li, Jing
Faggioni, Raffaella
Roskos, Lorin K.
Brose, Marcia S.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40262-023-01210-0
- URN
-
urn:nbn:de:101:1-2023082509240617378697
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:54 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ly, Neang S.
- Li, Jing
- Faggioni, Raffaella
- Roskos, Lorin K.
- Brose, Marcia S.
- SpringerLink (Online service)
Other Objects (12)
Sperm DNA fragmentation after radioiodine treatment for differentiated thyroid cancer
Clinico-pathological factors associated with radioiodine refractory differentiated thyroid carcinoma status
Assessing radioiodine therapy long-term outcomes in differentiated thyroid cancer using nomograms
Cabozantinib : Cabozantinib in der Behandlung des fortgeschrittenen Nierenzellkarzinoms
Ultrasound-guided implantation of radioactive 125I seed in radioiodine refractory differentiated thyroid carcinoma
Population Pharmacokinetics of Cabozantinib in Metastatic Renal Cell Carcinoma Patients: Towards Drug Expenses Saving Regimens
Molecular evidence reveals thyrotropin intervention enhances the risk of developing radioiodine-refractory differentiated thyroid carcinoma
Scoring system and a simple nomogram for predicting radioiodine refractory differentiated thyroid cancer: a retrospective study
Relationship between clinicopathologic factors and FDG avidity in radioiodine-negative recurrent or metastatic differentiated thyroid carcinoma
Germline polymorphisms of the NOD2 pathway may predict the effectiveness of radioiodine in differentiated thyroid cancer treatment
TERT promoter mutations contribute to adverse clinical outcomes and poor prognosis in radioiodine refractory differentiated thyroid cancer
Progressive Unilateral Proptosis and (18F) FDG-Avid Lesions Connoting Aggressive Disease in Radioiodine-Refractory Differentiated Thyroid Carcinoma
Sperm DNA fragmentation after radioiodine treatment for differentiated thyroid cancer
Clinico-pathological factors associated with radioiodine refractory differentiated thyroid carcinoma status
Assessing radioiodine therapy long-term outcomes in differentiated thyroid cancer using nomograms
Cabozantinib : Cabozantinib in der Behandlung des fortgeschrittenen Nierenzellkarzinoms
Ultrasound-guided implantation of radioactive 125I seed in radioiodine refractory differentiated thyroid carcinoma
Population Pharmacokinetics of Cabozantinib in Metastatic Renal Cell Carcinoma Patients: Towards Drug Expenses Saving Regimens
Molecular evidence reveals thyrotropin intervention enhances the risk of developing radioiodine-refractory differentiated thyroid carcinoma
Scoring system and a simple nomogram for predicting radioiodine refractory differentiated thyroid cancer: a retrospective study
Relationship between clinicopathologic factors and FDG avidity in radioiodine-negative recurrent or metastatic differentiated thyroid carcinoma
Germline polymorphisms of the NOD2 pathway may predict the effectiveness of radioiodine in differentiated thyroid cancer treatment
TERT promoter mutations contribute to adverse clinical outcomes and poor prognosis in radioiodine refractory differentiated thyroid cancer
Progressive Unilateral Proptosis and (18F) FDG-Avid Lesions Connoting Aggressive Disease in Radioiodine-Refractory Differentiated Thyroid Carcinoma
Sperm DNA fragmentation after radioiodine treatment for differentiated thyroid cancer
Clinico-pathological factors associated with radioiodine refractory differentiated thyroid carcinoma status
Assessing radioiodine therapy long-term outcomes in differentiated thyroid cancer using nomograms
Cabozantinib : Cabozantinib in der Behandlung des fortgeschrittenen Nierenzellkarzinoms
Ultrasound-guided implantation of radioactive 125I seed in radioiodine refractory differentiated thyroid carcinoma
Population Pharmacokinetics of Cabozantinib in Metastatic Renal Cell Carcinoma Patients: Towards Drug Expenses Saving Regimens
Molecular evidence reveals thyrotropin intervention enhances the risk of developing radioiodine-refractory differentiated thyroid carcinoma
Scoring system and a simple nomogram for predicting radioiodine refractory differentiated thyroid cancer: a retrospective study
Relationship between clinicopathologic factors and FDG avidity in radioiodine-negative recurrent or metastatic differentiated thyroid carcinoma
Germline polymorphisms of the NOD2 pathway may predict the effectiveness of radioiodine in differentiated thyroid cancer treatment
TERT promoter mutations contribute to adverse clinical outcomes and poor prognosis in radioiodine refractory differentiated thyroid cancer